Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2018-12-27

2018

Papoutsidakis Nikolaos

Κωνσταντίνος Νικ. Συρίγος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Πέτρος Μπακάκος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Γαρυφαλλιά Πουλάκου, Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ

Η σχέση του Bevacizumab με τις υποτροπές του Μη Μικροκυτταρικού Καρκίνου Πνεύμονα

Greek

The relation of Bevacizumab with the relapses of Non small cell lung cancer.

Introduction: The increased mortality of non-small cell lung cancer has led the
oncology community to turn to targeted treatments to address this. Bevacizumab is the
first anti-angiogenic agent that, through its binding to the VEGF receptor, inhibits tumor
angiogenesis and thus pushes cancer cells to death due to hypoxia and lack of
nutrients. Phase II and III studies have shown improvement in overall survival,
symptomatology of oncology patients and progression- free survival for platinum
chemotherapy combined with bevacizumab. The present retrospective study aims to
record the efficacy of bevacizumab in advanced non-small cell lung cancer. The
primary endpoints are progression- free survival in patients receiving bevacizumab
compared to those who did not receive and the improvement in symptomatology of the
patients associated with bevacizumab.
Method: We retrospectively examined 780 non-surgical non-small cell lung cancer
patients collected from the patient records file 2010 - 2015, the pulmonary clinics and
the oncology Unit of “Sotiria” Hospital of Athens.
Results: Statistically significant correlation was found between bevacizumab
chemotherapy and symptom augmentation (p = 0.023) with patients who received
bevacizumab chemotherapy-treated patients (45.2% vs. 35.7 %, p = 0.023). There was
no statistically significant correlation with the progression of the disease although the
relapse time of the patients receiving bevacizumab was greater than that of the
patients who received other drugs [6 (4, 10) vs. 5 (3, 9) p> 0.05]. Due to the limitation
of monocentric retrospective studies, further prospective and multicenter studies are
necessary to achieve more accurate results.

Health Sciences

Lung cancer, Chemotherapy, Anti-Angiogenic agent, Bevacizumab

No

0

Yes

25

41

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2838295